Quick Answer
Xenon Pharmaceuticals Inc. reported Operating Income Loss of -$373.07 million for the year ending 2025.
- Xenon Pharmaceuticals Inc. showed a decrease of -33.6% in Operating Income Loss from 2024 to 2025.
- This data is from Xenon Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Xenon Pharmaceuticals Inc.'s Operating Income Loss has declined by 11,732.2%.
- Historical annual values: Fiscal year 2025: -$373.07 million | Fiscal year 2024: -$279.30 million | Fiscal year 2023: -$214.05 million | Fiscal year 2022: -$129.14 million | Fiscal year 2021: -$78.99 million | Fiscal year 2020: -$31.30 million | Fiscal year 2019: -$42.82 million | Fiscal year 2018: -$38.04 million | Fiscal year 2017: -$32.58 million | Fiscal year 2016: -$24.82 million | Fiscal year 2015: -$9.36 million | Fiscal year 2014: $11.11 million | Fiscal year 2013: $9.71 million | Fiscal year 2012: -$3.15 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: